Emergent BioSolutions | EBS - Stock


Emergent BioSolutions reported $328.9M in Stock for its fiscal quarter ending in December of 2023.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Akebia Therapeutics USD 13M 2.61M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amarin USD 183.58M 12.32M Mar/2026
ANI Pharmaceuticals USD 143.47M 401K Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
Exelixis USD 26.6M 4.92M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
Lonza CHF 1.68B 163M Dec/2025
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Myriad Genetics USD 27.9M 2.7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Pacira USD 150.37M 2.49M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025